These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375 [TBL] [Abstract][Full Text] [Related]
6. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. De Jesus Moreno Moreno M Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119 [TBL] [Abstract][Full Text] [Related]
7. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. Weyer G; Eul A; Milde K; Wierich W; Herrmann WM Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459 [TBL] [Abstract][Full Text] [Related]
8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421 [TBL] [Abstract][Full Text] [Related]
9. Memantine in vascular dementia. Möbius HJ; Stöffler A Int Psychogeriatr; 2003; 15 Suppl 1():207-13. PubMed ID: 16191242 [TBL] [Abstract][Full Text] [Related]
10. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group. Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224 [TBL] [Abstract][Full Text] [Related]